ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Nanobody-based targeted cancer therapy and immunotherapy: fear not the future.Acta pharmacologica Sinica · 2026Review
- Potency and safety of novel [British journal of cancer · 2026Article
- Redox-driven speciation and colloid formation contribute the in vivo chemistry and organ deposition of Astatine-211.EJNMMI radiopharmacy and chemistry · 2026Article
- Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting.Scientific reports · 2025Article
- Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace.International journal of radiation oncology, biology, physics · 2025Article
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.International journal of molecular sciences · 2024Article
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies.Cancer cell international · 2024Review
- Review
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Radiosynthesis and preclinical evaluations of [American journal of nuclear medicine and molecular imaging · 2024Article
- Effective Treatment of SSTR2-Positive Small Cell Lung Cancer UsingMolecular pharmaceutics · 2023Article
- Molecular imaging for better theranostics.European journal of nuclear medicine and molecular imaging · 2023Article
- Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.Cancers · 2023Review
- In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy, particularly with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.